Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs Raxatrigine (Primary)
- Indications Neuropathic pain; Trigeminal neuralgia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Convergence Pharmaceuticals
- 04 May 2017 Status changed from active, no longer recruiting to completed.
- 18 Sep 2015 New trial record
- 24 Apr 2015 This trial was planned by Convergence. The Company has now been acquired by Biogen, according to Biogen media release.